The Beauty Health Company (NASDAQ:SKIN) Receives $2.81 Average Price Target from Analysts

The Beauty Health Company (NASDAQ:SKIN) has earned an average rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $2.8125.

Several equities analysts recently weighed in on SKIN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beauty Health in a research report on Friday, October 31st. Cowen reiterated a “hold” rating on shares of Beauty Health in a report on Monday, September 22nd. Stifel Nicolaus boosted their target price on shares of Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a report on Friday, August 1st. Roth Capital assumed coverage on shares of Beauty Health in a research report on Friday, September 19th. They set a “buy” rating and a $3.50 price target for the company. Finally, TD Cowen lifted their price target on shares of Beauty Health from $2.00 to $2.50 and gave the company a “hold” rating in a report on Monday, September 22nd.

Institutional Investors Weigh In On Beauty Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prescott Group Capital Management L.L.C. lifted its stake in shares of Beauty Health by 47.0% in the 1st quarter. Prescott Group Capital Management L.L.C. now owns 646,798 shares of the company’s stock valued at $867,000 after purchasing an additional 206,798 shares in the last quarter. Nuveen LLC purchased a new position in Beauty Health in the first quarter valued at approximately $59,000. AQR Capital Management LLC acquired a new position in Beauty Health during the first quarter valued at approximately $40,000. Goldman Sachs Group Inc. grew its stake in Beauty Health by 5.0% during the first quarter. Goldman Sachs Group Inc. now owns 665,706 shares of the company’s stock worth $892,000 after buying an additional 31,880 shares during the period. Finally, SCS Capital Management LLC acquired a new stake in shares of Beauty Health in the first quarter worth $67,000. 93.26% of the stock is currently owned by institutional investors and hedge funds.

Beauty Health Stock Performance

Shares of SKIN opened at $1.31 on Wednesday. Beauty Health has a 1 year low of $0.78 and a 1 year high of $2.69. The company’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.77. The company has a market capitalization of $167.03 million, a price-to-earnings ratio of -5.95 and a beta of 1.19. The company has a debt-to-equity ratio of 5.53, a quick ratio of 4.07 and a current ratio of 4.98.

Beauty Health (NASDAQ:SKIN) last released its earnings results on Thursday, November 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Beauty Health had a negative return on equity of 19.70% and a negative net margin of 3.87%.The firm had revenue of $70.66 million during the quarter, compared to analysts’ expectations of $68.33 million. Beauty Health has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Beauty Health will post -0.25 EPS for the current year.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.